Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (53)	5/14/2001 1:16:51 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1840

Tuck, I didn't comment early on GVAX vaccines. I think I did not. <g> Actually, I do not follow vaccines closely for good 12 months, so do not know what is new on this field. The VEGF comparison point is that in situation where we have well defined target and drug, fluctuation is something to expect. Difficulty to select doses and schedule. So, I have no idea how will CEGE transform personalized GVAX into generalized, or vaccine which can be used as normal drug. Regards the GVAX, trial is ongoing and they reported results from 30 pts who completed treatment period (and for whose vaccine preparation worked). Rest pts are still on trial. Also all pts have surgery, tumor mass are partially (advance cancer) or completely (early) removed. One additional thing on C225 and my early comment. IMCL CC give clear answer on failed pts in trial. These are pts who progressed on CPT-11 (+25% cancer growth). While CPT-11 is today the most potent agent for colorectal, stand-alone therapy isn't the best idea, imo. However, to give each pts chance for additional options after their cancer re-growth, combination therapy as second line therapy, oncologist prefers single agent first line therapy. So, +20% respond rate (this are probably all partial response) is very good. Nonetheless, median time before relapse and median survival (which is not disclosed) isn't right answer. The more important are mean survival and mean time before relapse. I have no idea why IMCL didn't disclose this data in PR (probably data were presented at ASCO). Does anyone have data on mean survival and mean time to progression for responded pts, as well for all pts in colorectal trial? I will appreciate results! Miljenko Miljenko